INTRODUCTION
ABSTRACT Vasoconstrictive properties of sympathomimetic drugs are the basis of their widespread use as decongestants and possible source of adverse responses. Insufficiently substantiated practice of combining decongestants in some marketed preparations, such are those containing phenylephrine and lerimazoline, may affect the overall contractile activity, and thus their therapeutic utility. This study aimed to examine the interaction between lerimazoline and phenylephrine in isolated rat aortic rings, and also to assess the substrate of the obtained lerimazoline-induced attenuation of phenylephrine contraction. Namely, while lower concentrations of lerimazoline (10 -6 M and especially 10 -7 M) expectedly tended to potentiate the phenylephrine-induced contractions, lerimazoline in higher concentrations in states that need prolonged administration is limited due to possibility of rebound congestion (rhinitis medicamentosa) on withdrawal [1] .
Phenylephrine is an efficacious a 1 receptor adrenergic agonist widely used as a nasal decongestant, where its utility has been attributed to a 1 adrenergic receptor-mediated vasoconstriction in nasal mucosa. This sympathomimetic agent is a synthetic selective a 1 -adrenergic agonist with mainly direct rather than indirect effects on adrenergic receptors. It was shown that the a 1 -adrenoceptor subtype mediating contraction to phenylephrine in rabbit corpus cavernosum has the characteristics of the a 1B -adrenoceptor subtype [2] . On the other hand, the results from another study, performed by use of antagonists which in binding studies show selectivity between the cloned a 1 -adrenoceptor subtypes, suggest that the contraction to phenylephrine of the rat thoracic aorta, mesenteric artery and pulmonary artery are mediated in part via the a 1D -subtype of adrenoceptors [3] . Finally, in a similarly designed experiment, it appeared that phenylephrine actions in the model of the rabbit cavernous artery may be antagonized only by an a 1A -adrenergic receptor blocker, suggesting that the predominant a 1 -adrenoceptor subtype involved in vasoconstriction of penile arteries was the a 1A -adrenoceptor [4] . From these pieces of evidence it may be concluded that all subtypes of the a 1 adrenergic receptor may contribute to vascular effects of phenylephrine.
Lerimazoline is a congener of oxymetazoline and xylometazoline which has been used in combination with phenylephrine in nasal decongestant preparations for half a century [5] . The pharmacological profile of this compound, reported earlier as St-71, trimizoline or trimazoline, is not sufficiently elucidated in the present literature [6] [7] [8] . It has been known for some time that lerimazoline possesses a substantial affinity for 5-HT 1D , and much less for 5-HT 1B receptors (Ki values 72 vs. 3480 nM) [9] ; more recently, it was found that it also demonstrates a high affinity for 5-HT 1A receptor (Ki=162.5 nM), while binding affinity estimates (Ki) for a 1 , 5-HT 2A and D 2 receptors were 6656, 4202 and 3437.5 nM, respectively [Rizvic et al., manuscript in preparation]. When evaluated for contractile activity in the rings of rabbit saphenous vein pretreated with all, prazosin, idazoxan and indomethacin, in order to exclude possible adrenergic a 1 , a 2 or prostaglandinmediated effects, respectively, EC 50 of lerimazoline (150 nM) was similar to that of the 5-HT1 B/D receptor agonist sumatriptan used as the positive control (EC 50 =220 nM) [9] . As it was shown that the rabbit saphenous vein did not functionally contract to 5-HT 1D receptor activation, while the high-affinity 5-HT 1B receptor antagonist displayed surmountable antagonism of the contractile effects of sumatriptan [10] , it can be indirectly concluded that contractile action of lerimazoline in that blood vessel should arise from activation of 5-HT 1B receptors. On the other hand, our recent results suggested that the lerimazoline-induced contractions in rat thoracic aorta, that varied in the range 40~55% of the contractions elicited by 10 -4 M phenylephrine, may be mediated mainly through non-a 1 adrenergic receptors, possibly of the 5-HT 2A subtype [Rizvic et al., manuscript in preparation], making it 'an atypical decongestant'. Such results were an impetus for assessment of the possible influences of lerimazoline on the contractile activity of phenylephrine, with a remote translational hypothesis that an interaction between these two vasoconstrictor agents, if revealed, may be useful in order to overcome rebound congestion seen on withdrawal of decongestants administered as single agents. We opted to study the putative interaction in the well-validated [11] , and in our previous experiments with lerimazoline already used rat aorta preparation, having in mind the recognized variability of agonist-induced actions in different vascular beds of rats, which depend on concentrations tested, type of receptor involved, basal vascular tone, vascular bed analyzed and the presence of possible pathological processes [12] [13] [14] .
METHODS
Aorta segments were taken from portions of 250~350 g weighing Wistar rats thoracic aorta, obtained from Military farm, Belgrade, Serbia. During treatment, rats were housed in clean transparent plastic cages with free access to tap water and pelleted food and kept in a conventional animal facility at a temperature of 22±1°C, relative humidity of 40~70% and the 12/12 h light/dark period, with lights on from 06:00. The animal study was performed after receiving approval of the Institutional Animal Care and Use Committee (approval No. 323-07-09231/2016-05/4, issued by the Veterinary Administration of the Republic of Serbia).
Reagents and drugs
Methiothepin hydrochloride (non-selective 5-HT antagonist), indomethacin hydrochloride (cyclooxygenase inhibitor), tetraethylammonium (TEA, the nonspecific K + channel blockers), L-NAME (nonspecific NOS inhibitor N w -nitro-L-arginine methyl ester) and prazosin hydrochloride (a 1 antagonist) were purchased from Sigma Aldrich (St. Louis, MO, USA). SB 269970 (selective 5-HT 7 antagonist), BRL 15572 (selective 5-HT 1D antagonist) and OHB 12 (NO scavenger) were purchased from Tocris (Bristol, UK). Lerimazoline hydrochloride and phenylephrine hydrochloride were kindly donated from Zdravlje Actavis, Leskovac, Serbia.
All drugs, except indomethacin, were prepared as concentrated stocks in distillated water before dilution to the final concentration each day and stored at 4°C during the experiment. Indomethacin was initially dissolved in 1% DMSO with subsequent dilutions carried out in distillated water. Drug concentrations are described as final molar concentrations in the tissue bath.
Experimental design
Isometric tension in aortic rings: Male Wistar rats were euthanized with carbon dioxide and the thoracic aortas were dissected, cleared of connective tissue, and cut into cylindrical segments of approximately 3 mm length while the blood vessels were bathed in Petri dishes containing modified Krebs-bicarbonate solution (KBS) of the following composition: 118.3 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 11 mM glucose. In a number of vessel preparations, the endothelial cell layer was removed by gently rubbing the luminal surface of the ring. Two stainless steel triangles were passed through the lumen of aortic rings, one of which was fixed to the organ bath wall whereas the other one was attached to the MLT0201 force displacement transducer (Panlab, Spain), mounted on a micrometer for manual adjustment of tension. The prepared aortic rings were mounted in a temperature-controlled organ baths (37°C) containing 25 ml Krebs solution which was continuously gassed with 95% O 2 and 5% CO 2 .
The signal was digitalized using the PowerLab/4SP data acquisition system (AD Instruments, Castle Hill, Australia) and changes in isometric tension were recorded with LabChart 6 Pro software (AD Instruments). Four organ baths were run in parallel.
Segments were allowed to equilibrate for 1 h in KBS, during which it was replaced every 10 min to prevent accumulation of metabolic end-products. During further 20 min, each aortic ring was stretched progressively to optimal length of 2 g for maximal isometric contraction and additionally was allowed to equilibrate for 40 min before commencing the experiment. In those protocols involving consecutive obtainment of two or three concentrationresponse curves, after completion of the previous concentrationresponse curve, the response was terminated by exchanging the KBS every 10 min for 30 min, thus allowing the aortic rings to return to their baseline tension. Each segment of rat aorta was used only for one experimental protocol.
Experimental protocol: The first series of experiments were aimed to measure constrictive strength of two agonists, and consisted of two parts performed in separate aorta rings. First, concentration-response curves of phenylephrine were generated by adding it to the organ bath in cumulative concentrations (10
Second, concentration-response curves of lerimazoline were constructed by adding it to the organ bath in cumulative concentrations (10 -7~3
×10
-4 M) and after washout, the contraction strength induced by 10 -4 M phenylephrine was measured. Cumulative concentration-response curves were generated by increasing the concentration of phenylephrine or lerimazoline in half-log increments, once the constriction to the previous concentration had stabilized [15, 16] .
The second series of experiments were aimed at assessing the effect of lerimazoline on contractile response induced by phenylephrine in aorta rings. Twenty min after obtaining the cumulative phenylephrine-induced contraction curve and washing out, lerimazoline was added directly to the organ bath. The effect of lerimazoline (2.1×10 -3 M, 10 -4 , 10 -6 or 10 -7 M) on the concentration response curves for phenylephrine (10 -8 , on the concentrationresponse curve for phenylephrine was assessed by measuring the contractile response in the absence and presence of 10 -4 M lerimazoline, respectively. The experiments without lerimazoline were performed in those cases where the respective inhibitor/ antagonist has previously affected the putative interaction between phenylephrine and lerimazoline.
Throughout the experiment, the constriction strength was expressed as a percentage of the maximum tension induced by the highest concentration of phenylephrine used in the given protocol.
Data analysis
Contractions produced by phenylephrine, lerimazoline or different antagonists/inhibitors on their own were measured as changes in tension from baseline (i.e. the tension immediately before the respective agonist administration) and expressed as a percentage of the phenylephrine maximum (mean±S.E.M). Agonist potency expressed as an EC 50 (the molar concentration necessary to produce 50% of the maximum agonist response) and maximum response (E max ) were determined from individual concentration-response curves by non-linear regression analysis.
In experiments with combined administration, EC 50 values of phenylephrine obtained in the presence and absence of lerimazoline or the used inhibitor/antagonist were compared by an unpaired t-test. An analysis of variance was used to compare EC 50 values and maximum responses obtained with phenylephrine, as well as phenylephrine and lerimazoline in the presence or absence of an inhibitor/antagonist. When the ANOVA indicated that differences existed between groups, Tukey's multiple-comparison test was applied to determine the source of variation [17] . The n values refer to the number of aorta vessels tested. Statistical significance was accepted at p<0.05.
RESULTS

Vascular responses to phenylephrine or lerimazoline
The agonists used in this study exhibited different contractile activity in rat thoracic aortas, irrespective of presence of endothelium. The addition of lerimazoline to the isolated tissues produced virtually no change in isometric tension over the concentration range of 10 -7~1 0 -5 M. For higher doses, in the range 10 -5~3
×10
-4 M, lerimazoline produced the maximal response of about 45% of the response induced by 10 -4 M phenylephrine, with pEC 50 =4.20 ( Fig. 1) . Specifically, phenylephrine started to increase tension from the first concentration of the drug tested (10 -8 M), with the pEC 50 =5.77. 
Vascular responses to phenylephrine in blood vessels exposed to different concentrations of lerimazoline
A quantitative comparative study was conducted to examine the effect of lerimazoline on response to phenylephrine. Higher concentrations of lerimazoline (2.1×10 -3 M and 10 -4 M) highly significantly attenuated maximal response (p<0.001) of phenylephrine concentration-response curve (E max =100±0.00% and 8.78±2.47%; pEC 50 being 5.46±0.31 and 3.06±0.72, p<0.05, for phenylephrine alone and with lerimazoline 2.1×10 -3 M, respectively, Fig. 2A ; and E max =100±0.00% and 9.91±4.58%; pEC 50 being 5.60±0.17 and 5.23±0.23, p>0.05, for phenylephrine alone and with lerimazoline 10 -4 M, respectively, Fig. 2B ). However, in tissue precontracted with lerimazoline (10 -6 and 10 -7 M), phenylephrine produced vasoconstrictor responses which were markedly more prominent then those observed in previous preparations, containing high concentrations of lerimazoline. Indeed, the lower concentrations of lerimazoline (10 -6 and 10 -7 M) produced a significant potentiation of the phenylephrine-induced contractions (Fig. 2C, D) , with fine differences between the effects of two concentrations. While lerimazoline (10 -7 M) produced a potentiation of the phenylephrine-induced contractions starting from the lowest concentration of phenylephrine (E max from 100±0.00% in the absence to 168.10±21.40% in the presence of lerimazoline, Fig. 2D 
Vascular responses to phenylephrine in presence of 10 -4 lerimazoline and different inhibitors/antagonists
In order to elucidate the mechanistic substrate for an unprecedented antagonism of contractile actions of phenylephrine exerted by lerimazoline, we chose to test the increasing concentrations of phenylephrine in presence of various ligands in two protocols: in the absence and presence of 10 -4 M lerimazoline. The pEC 50 values of combination of phenylephrine and lerimazoline obtained in the absence and presence of the given concentration of ligand, together with the respective number of blood vessel preparations, are given in Table 1 .
Effects of L-NAME and OHB 12 on the vasoconstrictor responses induced by phenylephrine and lerimazoline
A quantitative comparative study was performed with the goal to examine the effect of L-NAME (10 -4 M) and OHB 12 (10 -3 M) on responses to phenylephrine in the absence and presence of lerimazoline (10 -4 M). Primary, L-NAME potentiated the Emax to phenylephrine in thoracic aorta rings. The maximal contraction pretreated with L-NAME increased from 100% to 163.38±21.06% ( Fig. 3A ; *p<0.05). Lerimazoline (10 -4 M) caused a significant decrease (***p<0.001, Student's unpaired t-test) in the maximum contraction response to phenylephrine from 100% to 55.95±6.47%. The non-selective inhibitor of NO synthesis L-NAME completely reversed the lerimazoline-induced attenuation of the contractile effect of higher doses of phenylephrine. Under these conditions L-NAME increased significantly the maximum contractions of phenylephrine pretreated with lerimazoline (10 -4 M) from 55.95±6.47% to 84.59±10.49% ( Fig. 3B ; # p<0.05,). OHB 12 potentiated the E max to phenylephrine in thoracic aorta rings from 100% to 155.25±11.76% ( Fig. 3C ; **p<0.01). The maximum response to phenylephrine pretreated with lerimazoline was also significantly increased from 49.18±10.25% to 101.53±12.49% in the presence of OHB 12 ( Fig. 3D; ## p<0.01).
Effects of indomethacin and TEA on the vasoconstrictor responses induced by phenylephrine and lerimazoline
The interaction between phenylephrine and lerimazoline was examined in the presence of indomethacin or tetraethylammonium (TEA). While the cyclooxygenase inhibitor indomethacin (10 -5 M) did not change the basal tone of the vessels pretreated with lerimazoline ( Fig. 4A; p>0 .05), TEA (10 -3 M), a non-specific inhibitor of K + channels, potentiated the effect of phenylephrine in the thoracic aorta pretreated with lerimazoline. Namely, while TEA did not significantly affect the maximal response to phenylephrine in thoracic aorta rings (Fig. 4B) , it increased significantly the maximum contractions of phenylephrine pretreated with lerimazoline (10 -4 M), from 59.56±8.53% to 103.32±11.31% ( Fig. 4C; ## p<0.01).
Effects of methiothepin on the vasoconstrictor responses induced by phenylephrine and lerimazoline
The sensitivity of the interaction of phenylephrine and lerimazoline to antagonism by methiothepin was evaluated using three antagonist concentrations (10 -4 , 10 -6 and 3×10 
Effects of SB 269970 and BRL 15572 on the vasoconstrictor responses induced by phenyephrine and lerimazoline
The interaction between phenylephrine and lerimazoline was examined in the presence of higly selective 5-HT 7 receptor antagonist SB 269970 (Fig. 6A ) and selective 5-HT 1D receptor antagonist BRL 15572 (Fig. 6B) 
DISCUSSION
Our study revealed that there is an intricate interaction between phenylephrine, a strong vasoconstrictor selective for a 1 adrenergic receptors, and lerimazoline, an imidazoline ligand whose moderate vasoconstrictor actions have been related more to activation of 5-HT 1B [9] or 5-HT 2A [Rizvic et al., manuscript in preparation], than a1 adrenergic receptors. While lower concentrations of lerimazoline (10 -6 or 10 -7 M) tended to potentiate the vasoconstrictor activity of phenylephrine, lerimazoline in higher concentrations (10 -4 M and above) unveiled the potential to profoundly suppress the phenylephrine-induced vasoconstriction. The latter action was totally unexpected and asked for further elucidation.
Potentiation of phenylephrine-induced contractions by low lerimazoline concentrations could be explained as follows: pheny lephrine activated its a 1 receptors on vascular smooth muscle cells and exhibited potent vasoconstrictor effects, while lerimazoline may potentiated that action by eliciting additional contractile effects related to activation of 5-HT 1B [9] and/or 5-HT 2A receptors. On the other hand, it is not possible to propose a parsimonious explanation for the antagonistic action of higher concentrations of lerimazoline on contraction of rat aorta produced by phenylephrine. It has been noticed that cumulative addition of 10 -4 M lerimazoline (a concentration that significantly attenuated phenylephrine concentration-response curve), induced contraction of rat aorta of about 20% of the response induced by 10 -4 M phenylephrine ([5] ; the present results), while a one-time addition of the same lerimazoline concentration did not induce any change in the tone of the same vessel (the present results). However, in the latter, but not the former case, lerimazoline was added into organ bath after obtaining the cumulative phenylephrine-induced contraction curve and washing out, and in such settings a kind of homologous (related to a1 adrenergic receptors) or, more probably, heterologous (related to distinct subtypes of 5-HT receptors) desensitization, demonstrated and described in detail in rabbit aorta exposed to norepinephrine and angiotensin II [18] , could have taken its place.
Two main questions to be addressed are related to molecular messengers and receptor substrates of the observed attenuation of phenylephrine-induced rat aorta contraction achieved by lerimazoline, as a vasoconstrictive, rather than vasodilatory, agent on its own. Endothelium plays an important role in the regulation of vasoconstriction and vasodilation response elicited by different agonists. It releases vasodilatator factors, i.e. NO, EDHF and prostacyclin, as well as vasoconstrictor factors, i.e. endothelin 1, COX-derived vasoconstrictor products and superoxide anion [19, 20] . While NO inhibits the contractile response to many vasoconstrictors [21, 22] , EDHF causes endothelium-dependent hyperpolarization and relaxation in the rat aorta by opening K + channels, which cannot be overcome by the full blockade of NOS and cyclooxigenase [21] . As we used both, endothelium intact and denuded rings and the vascular activity of phenylephrine and lerimazoline, on their own and in combination, was unaffected by presence or absence of endothelium, it could be supposed that modulation of endothelial-derived vasoactive factors would not dominantly change the blood vessel reactivity to them. Nevertheless, the possibility of involvement of endogenously produced NO or prostaglandins in the mediation of phenylephrine -lerimazoline interaction was studied in the presence of the NO inhibitors L-NAME and OHB 12 or cyclooxygenase inhibitor indomethacin, respectively. In addition, we investigated the influence of non-selective K + inhibitor tetraethylammonium on attenuation of phenylephrine-induced contraction induced by lerimazoline. Lastly, the place of the 5-HT receptor pathway in the observed interaction was assessed using the highly selective 5-HT 1D receptor antagonist BRL 15572, 5-HT 7 receptor antagonist SB 269970 and non-selective 5-HT receptor antagonist methiothepin.
Pretreatment with L-NAME or OHB 12 reduced the lerimazoline-induced attenuation of the maximal contractile response to phenylephrine. This effect may be at least partially correlated via the NO-mediated modulation by lerimazoline of the phenylephrine contraction. However, assessment of relative contribution of this mechanism to the overall action of lerimazoline is hampered by the fact that both, L-NAME and OHB 12 significantly potentiated the phenylephrine contraction on its own. On the other hand, the opening of K + channels in vascular smooth muscle cells triggers membrane potential hyperpolarization and thus provides an important mechanism to prevent blood vessel contraction, the activities of certain K + -channels are inhibited by the non-selective blocker TEA. The opening of K + channels is probably activated by lerimazoline irrespective of phenylephrine, since there was no significant potentiation in the phenylephrine concentration-response curve pretreated with TEA. The described pattern of possible signaling mechanisms is not unique; as an example, a similar pattern was reported for amfepramone (diethylpropion), an appetitesuppressant drug with incompletely elucidated receptor/ channel binding profile, but with a substantial difference that amfepramone on its own tended to relax rather than contract rat aortic rings [23] .
In regard to the receptor pathways involved in the lerimazoline functional antagonism of the phenylephrine-induced rat aorta contraction, we concentrated on the 5-HT 7 receptor. Namely, it is well documented that 5-HT exerts a major part of its vasodilatory potential by activation of 5-HT 7 receptors, which can be prevented by use of the selective antagonist SB 269970. As an example, it is shown that 5-HT directly relaxes the rat superior mesenteric veins primarily through activation of the 5-HT 7 receptor [24] . Moreover, 5-HT was able to exert direct relaxant responses in canine basilar and middle cerebral arteries via the same, 5-HT 7 receptors [25] . On the other hand, BRL 15572, as the selective antagonist at the 5-HT 1D receptor, was used as a kind of negative control, having in mind that the canine external carotid vasodilator responses remained unaffected in presence of this ligand [26] . However, it appeared that not only the 5-HT 1D , but also the 5-HT 7 receptor was not involved in relaxant influences of lerimazoline. Nevertheless, the experiment with methiothepin gave a hint about the receptor substrate of the relaxant potential of lerimazoline. Namely, while methiothepin at 10 -4 M did not affect the action of lerimazoline, methiothepin at 10 -6 and 3×10 -7 M significantly reversed the lerimazolineinduced attenuation of the phenylephrine concentrationresponse curve, the lower concentration of methiothepin being devoid of the potential to interact with phenyleprine. If we assume that methiothepin in low concentrations did bind only to those receptors for which possesses the highest affinity, we can postulate that the 5-HT 2B subtype, to which methiothepin has Ki in the range 8.7~9.2 (IUPHAR database), was the first receptor blocked with methiothepin, significantly increasing in turn the contractile action of the blood vessel exposed to phenylephrine and lerimazoline in combination. This is in accordance with findings that 5-HT 2B receptors are located on the endothelial cell and, when activated, stimulate NO release [27] . Moreover, it was demonstrated that treatment with 5-HT 2B receptor antagonist abolishes a bypass-induced fall in blood pressure in Wistar rat in vivo [28] . It is worth to note that the second in a row binding site for methiothepin is the 5-HT 7 receptor (with Ki value in the range 8.4~9.4) (IUPHAR database), which suggests once more that the 5-HT 2B receptor is the probable receptor substrate of the relaxant actions of lerimazoline; however, further work is necessary before definite assignments can be made.
Finally, it shall be commented that the seemingly paradoxical pattern of actions of lerimazoline, with its moderate contractile activity, but also a capability to suppress the contraction induced by another, more effective contractile agent, should not be regarded as totally unprecedented. As an important example, Lamarre et al. [29] have reported that cocaine can exhibit both vasoconstricting and vasorelaxant effects. In fact, at a concentration devoid of effects on its own, cocaine potentiated the vasoconstriction produced by norepinephrine, as well the a1-selective agonists phenylephrine and methoxamine. On the other hand, higher concentrations of cocaine in combination with adrenergic agonists exerted a concentration-related relaxation, i.e. gave an inverted-U shaped (hormetic) dose-effect curve. The authors postulated that the relaxing component of the effect was due to activation of myosin light chain phosphatase by cocaine, shown by Li et al. [30] .
In conclusion, the present results indicate that the presence of lerimazoline, at a concentration close to and above that of phenylephrine, may result in the level of vasoconstriction less pronounced than that obtained with either of agents alone. In can be hypothesized that the interaction of lerimazoline with phenylephrine as one of standard decongestants, effected through receptor and signaling mechanisms probably involving the substrates other than the a1 adrenergic receptor, may suppress or slow down the development of the rebound congestion, which needs further research and assessment in clinical settings.
